Atropinization Criteria in Organophosphate Poisoning
Atropinization is achieved when you have successfully dried secretions (particularly bronchial), reversed bronchospasm, achieved a heart rate >80 bpm, and normalized blood pressure—NOT when tachycardia appears, as tachycardia should not stop atropine administration in OP poisoning. 1
Clinical Endpoints of Adequate Atropinization
The goal is complete resolution of the cholinergic crisis 1, specifically targeting:
Drying of secretions (most critical endpoint)
- Cessation of excessive salivation
- Reduction of bronchial secretions
- Control of lacrimation
Respiratory parameters
- Resolution of bronchospasm
- Clear breath sounds
- Adequate oxygenation
Cardiovascular stability
- Heart rate >80 bpm (bradycardia reversed)
- Stable blood pressure
- Important caveat: Peripheral vascular resistance normalization may require higher atropine doses than needed for other muscarinic symptoms 2
Pupillary response
- Pupils should dilate (mydriasis)
- Pin-point pupils indicate inadequate atropinization 3
Gastrointestinal symptoms
- Resolution of abdominal cramps
- Cessation of diarrhea and vomiting
Critical Dosing Principles
Adults: Start with 2-3 mg IV bolus, repeat every 20-30 minutes until atropinization achieved 1. Cumulative doses of 10-20 mg in the first 2-3 hours are typically required, with some patients needing up to 50 mg in 24 hours 1. The highest documented dose was 100 mg on admission and 100 mg/hour during follow-up 4.
Children: Use 0.05-0.1 mg/kg IV (significantly higher than standard pediatric resuscitation doses of 0.02 mg/kg). Titrate until complete resolution of cholinergic crisis. Do NOT stop atropine in the presence of tachycardia in children—unlike adults, repeated boluses do not cause cardiac arrhythmias in pediatric patients 1.
Common Pitfalls to Avoid
Stopping atropine due to tachycardia: This is the most dangerous error. Tachycardia is expected and acceptable during atropinization. The presence of persistent secretions with tachycardia means you need MORE atropine, not less 1.
Underdosing: Many clinicians use inadequate doses. Recent evidence shows that rapid dose escalation (doubling doses) achieves therapeutic endpoints faster 5. Aggressive atropinization is key to survival 6.
Using pupil size alone: While mydriasis is helpful, secretions and respiratory status are more reliable endpoints 1.
Premature discontinuation: Continue atropine until ALL muscarinic symptoms resolve, which may take days to weeks depending on the organophosphate compound 2.
Monitoring During Atropinization
- Continuous cardiac monitoring (watch for bradycardia reversal, not tachycardia development)
- Respiratory assessment (secretions, bronchospasm, need for mechanical ventilation)
- Blood pressure (hypotension may persist despite other symptom control and requires higher atropine doses 2)
- Plasma cholinesterase levels (though treatment is clinical, not laboratory-driven)
- Peripheral vascular resistance in patients with pre-existing vascular disease (may need exceptionally high doses 2)
Adjunctive Therapy
While atropine addresses muscarinic effects, also administer:
- Pralidoxime (oximes) for nicotinic effects, though efficacy remains controversial 7
- Benzodiazepines (midazolam 0.05-0.1 mg/kg or diazepam 0.2 mg/kg) for seizures and anxiety 1
- Mechanical ventilation with PEEP as needed 6
The FDA label confirms atropine's indication for organophosphate poisoning and emphasizes titration according to heart rate, PR interval, blood pressure, and symptoms 8.